These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24046050)

  • 1. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
    Iolascon G; Resmini G; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Denosumab - a new option in the treatment of osteoporosis].
    Franek E
    Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutical horizons in the management of postmenopausal osteoporosis.
    Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study.
    Brown JP; Dempster DW; Ding B; Dent-Acosta R; San Martin J; Grauer A; Wagman RB; Zanchetta J
    J Bone Miner Res; 2011 Nov; 26(11):2737-44. PubMed ID: 21735475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
    McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
    J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
    Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
    Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab for the treatment of osteoporosis.
    Zaheer S; LeBoff M; Lewiecki EM
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):461-70. PubMed ID: 25614274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of bisphosphonates in involutional osteoporosis.
    Ott SM
    J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.